Identification of borderline thyroid tumors by gene expression array analysis

Cancer

Volumn 115, Issue 23, 2009, Pages 5421-5431

  Arora, Nimmi ^a   Scognamiglio, Theresa ^a   Lubitz, Carrie C ^a   Moo, Tracy A ^a   Kato, Meredith A ^a   Zhu, Baixin ^a   Zarnegar, Rasa ^a   Chen, Yao Tseng ^a   Fahey III, Thomas J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

BRAF; Cytologic atypia; Follicular variant; Gene expression analysis; K means cluster analysis; Papillary thyroid carcinoma

Indexed keywords

B RAF KINASE; CALPAIN 3; CREATINE KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYSTEINE AND GLYCINE RICH PROTEIN 2; DEATH ASSOCIATED PROTEIN KINASE 2; DIPEPTIDYL PEPTIDASE IV; DUAL SPECIFICITY PHOSPHATASE 4; ENGULFMENT AND CELL MOTILITY 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROMODULIN; GENE PRODUCT; GLUTAMIC ACID ASPARTIC ACID RICH CARBOXY TERMINAL DOMAIN 1; GLYCINE AMIDINOTRANSFERASE; HIGH MOBILITY GROUP ADENINE THYMINE HOOK 2; LOW DENSITY LIPOPROTEIN; MATRILIN 2; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 10; PHOSPHONOFORMATE IMMUNOASSOCIATED PROTEIN 5; PLACENTAL GROWTH FACTOR; PROTEIN S; RETINOID X RECEPTOR GAMMA; SOMATOMEDIN BINDING PROTEIN 6; SYNDECAN 4; TENSIN 3; TETRASPANIN 12; TRANSCRIPTION FACTOR CP2 LIKE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE PHOSPHORYLASE 1;

ARTICLE; BENIGN TUMOR; BRAF GENE; CITED1 GENE; FGFR2 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HISTOLOGY; HMGA2 GENE; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; MET GENE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEPTOR GENE; THYROID PAPILLARY CARCINOMA;

CARCINOMA, PAPILLARY, FOLLICULAR; CLUSTER ANALYSIS; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 72249116704     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24616     Document Type: Article

References (39)

1. Mazzaferri EL. Solitary thyroid nodule. 2. Selective approach to management. Postgrad Med. 1981;70:107-109, 112, 116.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
3. Arora N, Scognamiglio T, Zhu B, Fahey TJ 3rd. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg. 2008;32:1237-1246.
4. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:16-18.
5. Franc B, de la Salmoniere P, Lange F, et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol. 2003;34:1092-1100.
6. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340.
7. Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand [A]. 1978;86A:483-486.
8. Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2002;26:1508-1514.
9. Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol. 2000; 8:181-183.
10. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch. 1996;429(4-5):213-219.
11. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342.
12. Choi YL, Kim MK, Suh JW, et al. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci. 2005;20:853-859.
13. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391-401.
14. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 2005;18:541-546.
15. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57.
16. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126:700-708.
17. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/ PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157-2167.
18. Chevillard S, Ugolin N, Vielh P, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004;10:6586-6597.
19. Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg. 2004;240:425-436; discussion 436-437.
20. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A. 2001;98:15044-15049.
21. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64:2898-2903.
22. Lubitz CC, Ugras SK, Kazam JJ, et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn. 2006;8:490-498; quiz 528.
23. Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587-1597.
24. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
25. Fontaine JF, Mirebeau-Prunier D, Franc B, et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertainmalignancy. Oncogene. 2008;27:2228-2236.
26. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15:191-205.
27. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466-470; discussion 470-471.
28. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202:247-251.
29. Zhu XL, Zhou XY, Zhu XZ. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma]. Zhonghua Bing Li Xue Za Zhi. 2005;34:270-274.
30. Pennelli N, Pennelli G, Merante Boschin I, Pelizzo MR. Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma. Ann Ital Chir. 2005;76:219-224.
31. Vasko VV, Gaudart J, Allasia C, et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol. 2004;151:779-786.
32. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology. 2004;45:39-46.
33. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology. 2002;41:357-362.
34. Nikiforov YE. RET/PTC rearrangement-a link between Hashimoto's thyroiditis and thyroid cancer. . . or not. J Clin Endocrinol Metab. 2006;91:2040-2042.
35. Rhoden KJ, Unger K, Salvatore G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab. 2006;91:2414-2423.
36. Rosai J. Handling of thyroid follicular patterned lesions. Endocr Pathol. 2005;16:279-283.
37. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107:1255-1264.
38. Vickery AL Jr. Thyroid papillary carcinoma. Pathological and philosophical controversies. Am J Surg Pathol. 1983;7: 797-807.
39. Evans HL. Encapsulated papillary neoplasms of the thyroid. A study of 14 cases followed for a minimum of 10 years. Am J Surg Pathol. 1987;11:592-597.